Physician profile
Donna D Catamero
NPI 1265746887
$279,171.36
in general payments reported to CMS, 2019-2025
22 companies · $95K in 2025
The $95K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,230 · 2022: $25K · 2023: $32K · 2024: $121K · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $136K · Travel and Lodging: $46K · Consulting Fee: $43K · Food and Beverage: $11K · Education: $6,261 · Grant: $3,597 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $136,057.00 |
| Travel and Lodging | $46,017.54 |
| Consulting Fee | $42,794.25 |
| Food and Beverage | $10,995.16 |
| Education | $6,260.99 |
| Grant | $3,596.81 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,990.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $199,894.85 | 2021-2025 | Carvykti, Darzalex, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $28,671.66 | 2022-2025 | Pomalyst, Abecma |
| Glaxosmithkline, LLC. | $27,442.58 | 2021-2025 | Blenrep |
| Genzyme Corporation | $4,934.55 | 2022-2025 | |
| Celgene Corporation | $4,542.39 | 2021-2024 | Pomalyst |
| Janssen Global Services, LLC | $3,997.50 | 2023-2024 | Rybrevant, Darzalex, Tecvayli |
| Legend Biotech USA INC. | $3,761.11 | 2022-2025 | Carvykti |
| Karyopharm Therapeutics INC. | $2,763.93 | 2021-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $1,416.17 | 2021-2025 | Ninlaro |
| The Binding Site INC. | $300.00 | 2025 | Freelite |
| Janssen Scientific Affairs, LLC | $232.61 | 2023-2024 | Talvey, Imbruvica, Tecvayli |
| Kite Pharma, INC. | $194.56 | 2024-2025 | Yescarta |
| F. Hoffmann-La Roche Ag | $180.00 | 2025 | |
| Genentech USA, INC. | $137.06 | 2021-2025 | Venclexta, Gazyva |
| Amgen INC. | $125.00 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $113.57 | 2025 | Lynozyfic |
| Pfizer INC. | $110.77 | 2023-2025 | |
| Abbvie INC. | $110.35 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $108.08 | 2021-2024 | |
| Genentech, INC. | $95.05 | 2023 | |
| Merck Sharp & Dohme LLC | $21.55 | 2024 | Prevymis, Recarbrio, Zerbaxa |
| Kadmon Pharmaceuticals LLC | $18.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Catamero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.